Evercore ISI analyst Vijay Kumar added Caris Life Sciences (CAI) to the firm’s “Tactical Outperform” list. The stock has pulled back 20% since Q2 while “peers have hung in well,” notes the analyst, who expects a “solid” revenue beat when the company reports Q3 results. Evercore has an Outperform rating and $40 price target on Caris shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences publishes study in Oncotarget on MI Cancer Seek
- Caris Life Sciences publishes results of antibody-drug study in breast cancer
- Caris Life Sciences price target raised to $45 from $38 at BTIG
- Caris Life Sciences price target raised to $42 from $34 at Citi
- Caris Life Sciences Reports Strong Q2 2025 Results